The Cystic Fibrosis Foundation's successful business model was at the center of a congressional briefing in Washington, D.C., today, which focused on strategies for jump-starting drug development for rare diseases.
Site Search
Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.
This award is part of the Cystic Fibrosis Foundation’s Physician Scientist Training Program and is designed to introduce residents to cystic fibrosis research with the goal to develop and maintain interest in a career in CF research or as a CF care provider.
This award program is intended to fund training for physicians interested in developing expertise in the endocrinologic care of patients with cystic fibrosis.
CF Foundation President and CEO Robert J. Beall, Ph.D. testified today before the House of Representatives' Energy and Commerce Committee at a hearing entitled, “21st Century Cures: Incorporating the Patient Perspective.”
Although I'm glad that my two children with cystic fibrosis will soon have the opportunity to try Trikafta, I am also a little worried about whether they will have side effects and how well they will do on the drug long-term.
Check your award letter for reporting requirements and due dates.
This program is intended to offer eligible awardees assistance with student loan payments for educational loans acquired in the pursuit of a graduate-level degree.
A diverse group of talented academic investigators leads the cystic fibrosis research community. The Cystic Fibrosis Foundation is pleased to support these investigators through a variety of opportunities.
The Cystic Fibrosis Foundation is aware that many labs and clinical studies have been impacted by the recent response to COVID-19. It is the CF Foundation's intention to work with funding applicants and CF Foundation-funded investigators to minimize the effects of the pandemic on research that is critical to advancing the mission of the Foundation.